DESIPRAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Desipramine Hydrochloride patents expire, and when can generic versions of Desipramine Hydrochloride launch?
Desipramine Hydrochloride is a drug marketed by Actavis Totowa, Alembic, Amneal Pharms Co, Ani Pharms, Heritage Pharms, Novast Labs, Sandoz, and Usl Pharma. and is included in sixteen NDAs.
The generic ingredient in DESIPRAMINE HYDROCHLORIDE is desipramine hydrochloride. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desipramine Hydrochloride
A generic version of DESIPRAMINE HYDROCHLORIDE was approved as desipramine hydrochloride by ACTAVIS TOTOWA on June 5th, 1987.
Summary for DESIPRAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 16 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 89 |
Clinical Trials: | 61 |
Patent Applications: | 1,509 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DESIPRAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DESIPRAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
King's College London | Phase 3 |
NHS Lothian | Phase 3 |
University College, London | Phase 3 |
Pharmacology for DESIPRAMINE HYDROCHLORIDE
Drug Class | Tricyclic Antidepressant |